[{"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-001", "question": "A 43-year-old woman undergoes bilateral DIEP free flap breast reconstruction after nipple-sparing mastectomy. Intraoperatively, the right flap requires an 11-cm venous graft to reach the internal mammary vein, and flow is satisfactory at closure. On postoperative day 3, she develops progressive swelling and violaceous discoloration of the right flap with brisk bleeding on pinprick and Dopplerable arterial signal in the pedicle but no venous signal. Exploration shows a patent arterial anastomosis, a soft flap, and a congested, thrombotic venous graft with limited nearby recipient veins. The contralateral internal mammary and thoracodorsal systems are already occupied by the left flap. Which salvage strategy offers the highest likelihood of durable flap survival?", "options": ["Shortening the flap pedicle with reanastomosis directly to the internal mammary vein after partial flap debulking to reduce reach and venous load", "Use of a retrograde internal mammary vein anastomosis via a newly dissected contralateral internal mammary perforator and interposition venous graft", "Creation of a venous cross-over (cross-chest) anastomosis from the congested flap vein to a contralateral DIEP flap superficial inferior epigastric vein branch", "Conversion of the free flap to a pedicled bipedicled transverse rectus abdominis myocutaneous (TRAM) flap by re-establishing inferior epigastric inflow and rotating the flap on its native pedicle", "Immediate complete flap removal and delayed reconstruction with a latissimus dorsi flap and implant after chemotherapy and radiation are completed"], "answer": "C", "answer_index": 2, "explanation": "Venous cross-over using a contralateral flap vein (often SIEV) is a recognized, high-yield salvage when ipsilateral recipient veins are exhausted, preserving a viable free flap. Shortening the pedicle (A) is not feasible given the reach problem and does not address lack of recipient vein; retrograde IMV with another vein graft (B) adds another long, failure-prone segment. Converting to pedicled TRAM (D) is not realistic once the flap is fully disconnected. Immediate flap loss (E) is last resort and avoids a proven microvascular salvage option.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Bilateral DIEP free flaps; right side required an 11‑cm venous graft to IMV; POD3 venous congestion with patent arterial signal and failed/thrombotic venous graft; limited ipsilateral recipient veins; contralateral IMV and thoracodorsal systems already used by left flap. Need a salvage option that avoids another long, failure‑prone graft and uses available venous outflow from the contralateral flap.\\n\\nBest interpretation: Venous cross‑over using the contralateral flap’s superficial inferior epigastric vein (SIEV) branch (choice C) is a well‑described salvage when ipsilateral options are exhausted and the other free flap is in place and well perfused.\\n\\nChoice analysis: A is not feasible—shortening the pedicle doesn’t create a new recipient and reach is already problematic. B requires another long interposition graft and complex routing, increasing thrombosis risk. D is unrealistic once the DIEP has been fully dissected and converted to a true free flap; re‑establishing an inferior epigastric pedicle is not practical. E is a last resort and inferior to a viable microvascular salvage. No other option rivals C for durable flap survival.\\n\\nMinimal fix: Clarify in the stem that the contralateral DIEP flap’s SIEV branch is available and patent to reinforce option C’s feasibility.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Bilateral DIEP free flaps; right side required an 11‑cm venous graft to IMV; POD3 venous congestion with patent arterial signal and failed/thrombotic venous graft; limited ipsilateral recipient veins; contralateral IMV and thoracodorsal systems already used by left flap. Need a salvage option that avoids another long, failure‑prone graft and uses available venous outflow from the contralateral flap.\n\nBest interpretation: Venous cross‑over using the contralateral flap’s superficial inferior epigastric vein (SIEV) branch (choice C) is a well‑described salvage when ipsilateral options are exhausted and the other free flap is in place and well perfused.\n\nChoice analysis: A is not feasible—shortening the pedicle doesn’t create a new recipient and reach is already problematic. B requires another long interposition graft and complex routing, increasing thrombosis risk. D is unrealistic once the DIEP has been fully dissected and converted to a true free flap; re‑establishing an inferior epigastric pedicle is not practical. E is a last resort and inferior to a viable microvascular salvage. No other option rivals C for durable flap survival.\n\nMinimal fix: Clarify in the stem that the contralateral DIEP flap’s SIEV branch is available and patent to reinforce option C’s feasibility.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-002", "question": "A 56-year-old man presents with progressive gait ataxia, urinary urgency, and cognitive slowing over 10 months. MRI shows ventriculomegaly out of proportion to mild cortical atrophy, but in addition there is a subtle nodular T1-hypointense, T2-hyperintense lesion in the posterior third ventricle near the aqueduct, with minimal enhancement and no diffusion restriction. Cine phase-contrast MRI demonstrates preserved CSF stroke volume at the cerebral aqueduct. A high-volume lumbar tap test produces only transient, equivocal improvement. Which is the most appropriate next neurosurgical management?", "options": ["Programmable ventriculoperitoneal shunt placement without further workup, given classic normal-pressure hydrocephalus symptoms", "Endoscopic third ventriculostomy with concurrent biopsy of the third ventricular lesion", "Endoscopic biopsy and possible debulking of the third ventricular lesion without CSF diversion, followed by observation", "Stereotactic radiosurgery targeted to the third ventricular lesion followed by reassessment of hydrocephalus", "External lumbar drainage trial over 72 hours before deciding on shunt placement"], "answer": "B", "answer_index": 1, "explanation": "The combination of ventriculomegaly and a small obstructive-appearing lesion near the aqueduct suggests a secondary obstructive hydrocephalus rather than idiopathic NPH; ETV addresses obstruction and allows tissue diagnosis for a possible low-grade tumor or colloid-like lesion. Shunting alone (A, E) ignores a likely focal obstructive cause and risks shunt dependence. Biopsy alone (C) does not treat hydrocephalus. SRS (D) is premature without histology and does not immediately relieve CSF obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Progressive gait ataxia, urinary urgency, cognitive slowing (NPH-like triad) plus MRI with ventriculomegaly and a discrete posterior third-ventricle lesion near the aqueduct. Lesion is T1-hypointense/T2-hyperintense, minimally enhancing, no diffusion restriction, suggesting a low-grade, likely benign mass partially obstructing CSF flow. Cine MRI shows preserved CSF stroke volume at the aqueduct, and lumbar tap test is only equivocal, weakening the diagnosis of idiopathic NPH. These features point to secondary obstructive hydrocephalus at the level of the third ventricle/aqueduct.\\nLogical evaluation: Option B (endoscopic third ventriculostomy with concurrent biopsy) both addresses a likely obstructive component and provides tissue diagnosis in a minimally invasive way, fitting modern neurosurgical practice. A and E focus on shunting without addressing an anatomic lesion; C neglects CSF diversion; D offers SRS without histology and no immediate CSF relief. Thus, a single best answer is clearly supported and matches the key.\\nMedical accuracy: Imaging interpretation, pathophysiologic reasoning, and management hierarchy are consistent with contemporary standards.\\nMinimal fix: Clarify that cine MRI suggests at least partial flow at the aqueduct but does not exclude focal obstruction, reinforcing ETV rationale, though the item is already acceptable.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Progressive gait ataxia, urinary urgency, cognitive slowing (NPH-like triad) plus MRI with ventriculomegaly and a discrete posterior third-ventricle lesion near the aqueduct. Lesion is T1-hypointense/T2-hyperintense, minimally enhancing, no diffusion restriction, suggesting a low-grade, likely benign mass partially obstructing CSF flow. Cine MRI shows preserved CSF stroke volume at the aqueduct, and lumbar tap test is only equivocal, weakening the diagnosis of idiopathic NPH. These features point to secondary obstructive hydrocephalus at the level of the third ventricle/aqueduct.\nLogical evaluation: Option B (endoscopic third ventriculostomy with concurrent biopsy) both addresses a likely obstructive component and provides tissue diagnosis in a minimally invasive way, fitting modern neurosurgical practice. A and E focus on shunting without addressing an anatomic lesion; C neglects CSF diversion; D offers SRS without histology and no immediate CSF relief. Thus, a single best answer is clearly supported and matches the key.\nMedical accuracy: Imaging interpretation, pathophysiologic reasoning, and management hierarchy are consistent with contemporary standards.\nMinimal fix: Clarify that cine MRI suggests at least partial flow at the aqueduct but does not exclude focal obstruction, reinforcing ETV rationale, though the item is already acceptable.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-003", "question": "A 68-year-old man with cT3N1M0 distal esophageal adenocarcinoma receives neoadjuvant chemoradiation with carboplatin/paclitaxel and 50.4 Gy in 28 fractions using IMRT. He has severe baseline interstitial lung disease (UIP pattern) with DLCO 35% predicted. At multidisciplinary review before simulation, the radiation oncologist must choose a planning goal that most reduces the risk of fatal radiation pneumonitis while still allowing adequate target coverage. Which constraint is most critical to prioritize in this scenario?", "options": ["Mean lung dose (MLD) <10 Gy, even if heart V40 increases modestly", "Total lung V20 <20%, accepting an MLD up to 15 Gy", "Ipsilateral lung V30 <15% with no specific constraint on contralateral lung", "Total lung V5 <40% while relaxing V20 and MLD constraints", "Heart V30 <30% with no further reduction in lung dose beyond standard constraints"], "answer": "A", "answer_index": 0, "explanation": "In patients with severe underlying ILD, data show the mean lung dose is the best single predictor of lethal pneumonitis; keeping MLD as low as possible (often <10 Gy) is paramount, even if cardiac doses increase somewhat. V20 (B) is important but less predictive in ILD compared with MLD. Ipsilateral V30 constraints (C) and V5 (D) are less strongly tied to high-grade pneumonitis. Prioritizing heart sparing (E) over lung constraints is inappropriate in a patient at extreme pulmonary risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Distal esophageal chemoradiation to 50.4 Gy, IMRT; patient has severe baseline interstitial lung disease with UIP pattern and DLCO 35%; question explicitly asks which planning goal most reduces risk of *fatal* radiation pneumonitis while still allowing adequate target coverage. Severe ILD/UIP is known to confer very high pneumonitis risk, and several series suggest mean lung dose is the strongest single dosimetric predictor of lethal pneumonitis in this population. Option A (MLD <10 Gy even at expense of modest heart V40 increase) directly targets the most predictive lung parameter and appropriately accepts increased cardiac dose given extreme pulmonary vulnerability. \\nOption B prioritizes V20 with higher allowed MLD and is thus inferior given MLD’s stronger association with severe pneumonitis in ILD. Option C ignores contralateral/total lung; lethal pneumonitis risk depends on total functional lung. Option D focuses on V5, which is less clearly linked to high-grade toxicity than MLD in ILD. Option E prioritizes cardiac sparing over lung in a patient whose dominant risk is pulmonary. The question is clear, single-best, and medically current.\\nMinimal fix: Cite “total lung MLD <10 Gy” explicitly to avoid ambiguity about which lung volume is meant.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Distal esophageal chemoradiation to 50.4 Gy, IMRT; patient has severe baseline interstitial lung disease with UIP pattern and DLCO 35%; question explicitly asks which planning goal most reduces risk of *fatal* radiation pneumonitis while still allowing adequate target coverage. Severe ILD/UIP is known to confer very high pneumonitis risk, and several series suggest mean lung dose is the strongest single dosimetric predictor of lethal pneumonitis in this population. Option A (MLD <10 Gy even at expense of modest heart V40 increase) directly targets the most predictive lung parameter and appropriately accepts increased cardiac dose given extreme pulmonary vulnerability. \nOption B prioritizes V20 with higher allowed MLD and is thus inferior given MLD’s stronger association with severe pneumonitis in ILD. Option C ignores contralateral/total lung; lethal pneumonitis risk depends on total functional lung. Option D focuses on V5, which is less clearly linked to high-grade toxicity than MLD in ILD. Option E prioritizes cardiac sparing over lung in a patient whose dominant risk is pulmonary. The question is clear, single-best, and medically current.\nMinimal fix: Cite “total lung MLD <10 Gy” explicitly to avoid ambiguity about which lung volume is meant.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-004", "question": "A 63-year-old woman undergoes right upper lobectomy via VATS for a 2.8-cm peripheral squamous cell carcinoma. On postoperative day 5 she develops acute dyspnea and subcutaneous emphysema. Chest CT shows a large posterior membranous tracheal defect 2 cm above the carina communicating with a loculated right pleural air collection. Bronchoscopy confirms a 1.5-cm full-thickness laceration with necrotic edges in a fragile, steroid-exposed airway. The right main bronchus is intact; there is no mediastinitis and she is hemodynamically stable but ventilator dependent. Which operative strategy provides the best chance of durable repair and respiratory recovery?", "options": ["Primary end-to-end tracheal resection with anastomosis and neck flexion, without tissue interposition", "Right posterolateral thoracotomy with direct tracheal defect closure reinforced by a pedicled intercostal muscle flap", "Cervical approach with placement of a covered tracheal stent and no open repair", "Right thoracotomy with tracheal defect closure buttressed by a pedicled latissimus dorsi flap and distal tracheostomy below the repair", "Clamshell thoracotomy with carinal resection and reconstruction to isolate the injured segment"], "answer": "B", "answer_index": 1, "explanation": "A posterior distal tracheal laceration communicating with the ipsilateral pleura after lobectomy is best approached via thoracotomy with direct repair and vascularized intercostal muscle buttress, preserving remaining lung and avoiding extensive resection. Circumferential resection (A, E) is excessive and risky in a fragile airway. Covered stenting alone (C) in a full-thickness laceration with necrotic edges risks dehiscence and mediastinitis. Latissimus flap plus distal tracheostomy (D) is more morbid and generally unnecessary compared with intercostal muscle reinforcement.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Large (1.5‑cm) full‑thickness posterior membranous tracheal laceration, 2 cm above carina; communicates with ipsilateral pleural air collection after right upper lobectomy; necrotic edges in steroid‑exposed, fragile airway; right main bronchus intact; no mediastinitis; patient stable but ventilator‑dependent. These favor operative repair via ipsilateral thoracic approach with vascularized tissue buttress.\\nOption B (right posterolateral thoracotomy with direct closure plus pedicled intercostal muscle flap) matches standard management: access from right chest to posterior distal trachea, primary closure and reinforcement, preserving remaining lung.\\nOption A (circumferential tracheal resection/anastomosis without tissue buttress) is excessive and risky in a fragile, necrotic, steroid‑exposed airway and omits vascularized coverage.\\nOption C (covered stent alone) is inappropriate for a sizable full‑thickness defect with necrotic edges and pleural communication, risking persistent leak and infection.\\nOption D adds distal tracheostomy and latissimus flap, significantly more morbid without clear added benefit over intercostal flap.\\nOption E (clamshell with carinal resection) is overly radical given intact carina and right main bronchus.\\nMinimal fix: Explicitly state that remaining lung parenchyma is functional and that pleural collection is confined, to further justify lung‑sparing thoracic repair with muscle buttress.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Large (1.5‑cm) full‑thickness posterior membranous tracheal laceration, 2 cm above carina; communicates with ipsilateral pleural air collection after right upper lobectomy; necrotic edges in steroid‑exposed, fragile airway; right main bronchus intact; no mediastinitis; patient stable but ventilator‑dependent. These favor operative repair via ipsilateral thoracic approach with vascularized tissue buttress.\nOption B (right posterolateral thoracotomy with direct closure plus pedicled intercostal muscle flap) matches standard management: access from right chest to posterior distal trachea, primary closure and reinforcement, preserving remaining lung.\nOption A (circumferential tracheal resection/anastomosis without tissue buttress) is excessive and risky in a fragile, necrotic, steroid‑exposed airway and omits vascularized coverage.\nOption C (covered stent alone) is inappropriate for a sizable full‑thickness defect with necrotic edges and pleural communication, risking persistent leak and infection.\nOption D adds distal tracheostomy and latissimus flap, significantly more morbid without clear added benefit over intercostal flap.\nOption E (clamshell with carinal resection) is overly radical given intact carina and right main bronchus.\nMinimal fix: Explicitly state that remaining lung parenchyma is functional and that pleural collection is confined, to further justify lung‑sparing thoracic repair with muscle buttress.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-005", "question": "A 72-year-old man with prior left common femoral endarterectomy and iliac stenting presents with limb-threatening ischemia of the left leg (Rutherford class 5). Angiography shows occluded left external iliac stent and a heavily calcified common femoral artery with poor clamp sites. The profunda femoris is patent with robust collaterals; the superficial femoral artery (SFA) is chronically occluded. Aortobifemoral bypass is contraindicated due to prior hostile laparotomy and significant cardiopulmonary comorbidity. Which revascularization strategy most reliably restores durable inflow to the profunda with acceptable operative risk?", "options": ["Endovascular recanalization and relining of the external iliac stent only, without addressing the common femoral artery", "Retroperitoneal ilio-profunda bypass from the ipsilateral common iliac artery to the profunda femoris artery", "Axillo-bifemoral bypass using an 8-mm ringed PTFE graft with proximal hood anastomosis to the axillary artery", "Femoral-femoral crossover bypass from the contralateral common femoral artery to the ipsilateral profunda femoris artery", "Hybrid repair with endovascular iliac stent relining plus open common femoral endarterectomy and patch angioplasty to the profunda origin"], "answer": "E", "answer_index": 4, "explanation": "A hybrid approach-iliac stent relining to restore inflow plus open common femoral endarterectomy/patch to the profunda-directly corrects both inflow and the key outflow vessel while avoiding aortic surgery. Isolated iliac relining (A) leaves the diseased CFA uncorrected. Ilio-profunda bypass (B) is more invasive than necessary in a hostile abdomen. Axillo-bifemoral (C) and fem-fem crossover (D) ignore the ipsilateral inflow lesion and are less durable or anatomically suboptimal in this context.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Limb-threatening ischemia (Rutherford 5), occluded external iliac stent, heavily calcified common femoral artery with poor clamp sites, patent profunda with robust collaterals, chronically occluded SFA, and contraindication to aortobifemoral bypass due to hostile abdomen and comorbidities. The clinical priority is durable inflow plus optimized profunda outflow without major aortic surgery.\\nOption E (hybrid iliac relining + CFA endarterectomy/patch to profunda) directly treats the inflow lesion (iliac stent occlusion) and the key outflow vessel (profunda origin) in a less invasive, standard-of-care fashion and is consistent with current hybrid limb salvage strategies.\\nOption A ignores severe CFA disease and will not provide durable profunda inflow. Option B (ilio-profunda bypass) still requires significant proximal dissection and is more invasive than a hybrid CFA exposure, especially with hostile abdomen. Option C (axillo-bifemoral) and D (fem-fem) both bypass to diseased ipsilateral CFA/profunda region and do not correct the critical local inflow/outflow pathology, with lower long-term patency.\\nMain medical issues: None significant; overall accurate and contemporary.\\nMinimal fix: Clarify that the contralateral iliac inflow is adequate to avoid any ambiguity about fem-fem feasibility, though it would still be inferior to E.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Limb-threatening ischemia (Rutherford 5), occluded external iliac stent, heavily calcified common femoral artery with poor clamp sites, patent profunda with robust collaterals, chronically occluded SFA, and contraindication to aortobifemoral bypass due to hostile abdomen and comorbidities. The clinical priority is durable inflow plus optimized profunda outflow without major aortic surgery.\nOption E (hybrid iliac relining + CFA endarterectomy/patch to profunda) directly treats the inflow lesion (iliac stent occlusion) and the key outflow vessel (profunda origin) in a less invasive, standard-of-care fashion and is consistent with current hybrid limb salvage strategies.\nOption A ignores severe CFA disease and will not provide durable profunda inflow. Option B (ilio-profunda bypass) still requires significant proximal dissection and is more invasive than a hybrid CFA exposure, especially with hostile abdomen. Option C (axillo-bifemoral) and D (fem-fem) both bypass to diseased ipsilateral CFA/profunda region and do not correct the critical local inflow/outflow pathology, with lower long-term patency.\nMain medical issues: None significant; overall accurate and contemporary.\nMinimal fix: Clarify that the contralateral iliac inflow is adequate to avoid any ambiguity about fem-fem feasibility, though it would still be inferior to E.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-006", "question": "A 45-year-old woman with a 1.7-cm left adrenal incidentaloma has mild hypertension and intermittent headaches. She is on a thiazide diuretic. Labs show: K 3.3 mmol/L, plasma aldosterone 15 ng/dL, plasma renin activity 0.1 ng/mL/h (suppressed), and aldosterone-renin ratio (ARR) of 150 (elevated). Confirmatory saline suppression test is borderline. Adrenal vein sampling (AVS) without cosyntropin stimulation reveals: cortisol-corrected aldosterone lateralization index (LI) of 2.2, but contralateral suppression index <0.3. Which is the most appropriate next step in management?", "options": ["Left laparoscopic adrenalectomy, given imaging-concordant unilateral lesion and contralateral suppression", "Continue medical therapy with mineralocorticoid receptor antagonists because lateralization index is below traditional cutoff", "Repeat AVS with cosyntropin stimulation to clarify lateralization before deciding on surgery", "Proceed to partial (cortical-sparing) resection of the left adrenal nodule to preserve adrenal function", "Observation without intervention, as results suggest nonfunctioning incidentaloma"], "answer": "A", "answer_index": 0, "explanation": "Current AVS interpretation emphasizes both lateralization and contralateral suppression; a low contralateral aldosterone/cortisol ratio (<0.3) strongly indicates unilateral disease even with modest LI, especially with concordant imaging and biochemical primary aldosteronism. Medical therapy (B) or observation (E) ignores resectable unilateral disease. Repeating AVS (C) is unnecessary given clear suppression. Partial adrenalectomy (D) is not standard for unilateral aldosterone-producing adenomas and risks recurrence.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Hypertensive 45-year-old woman with hypokalemia on thiazide, elevated ARR (150) with suppressed renin and borderline saline suppression, plus a 1.7‑cm unilateral adrenal nodule. AVS shows modest lateralization index (2.2) but marked contralateral suppression (<0.3), imaging-concordant with the left nodule. These findings are consistent with unilateral primary aldosteronism localized to the left adrenal and resectable disease.\\nLogical assessment: Among the options, left laparoscopic adrenalectomy (A) is clearly superior. (B) medical therapy is used when disease is bilateral or patient is not a surgical candidate; here AVS suggests unilateral disease. (C) repeating AVS with cosyntropin isn’t typically needed when there is strong contralateral suppression plus concordant imaging. (D) cortical-sparing adrenalectomy is not standard for aldosterone-producing adenomas. (E) observation ignores clear biochemical hyperaldosteronism.\\nMedical accuracy: The AVS interpretation and management recommendation align with contemporary Endocrine Society guidance and AVS literature recognizing contralateral suppression as strong evidence of unilateral disease when imaging is concordant. No major inaccuracies identified.\\nMinimal fix: Specify guideline or numeric thresholds used for LI and contralateral suppression in the stem to further standardize interpretation across institutions.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Hypertensive 45-year-old woman with hypokalemia on thiazide, elevated ARR (150) with suppressed renin and borderline saline suppression, plus a 1.7‑cm unilateral adrenal nodule. AVS shows modest lateralization index (2.2) but marked contralateral suppression (<0.3), imaging-concordant with the left nodule. These findings are consistent with unilateral primary aldosteronism localized to the left adrenal and resectable disease.\nLogical assessment: Among the options, left laparoscopic adrenalectomy (A) is clearly superior. (B) medical therapy is used when disease is bilateral or patient is not a surgical candidate; here AVS suggests unilateral disease. (C) repeating AVS with cosyntropin isn’t typically needed when there is strong contralateral suppression plus concordant imaging. (D) cortical-sparing adrenalectomy is not standard for aldosterone-producing adenomas. (E) observation ignores clear biochemical hyperaldosteronism.\nMedical accuracy: The AVS interpretation and management recommendation align with contemporary Endocrine Society guidance and AVS literature recognizing contralateral suppression as strong evidence of unilateral disease when imaging is concordant. No major inaccuracies identified.\nMinimal fix: Specify guideline or numeric thresholds used for LI and contralateral suppression in the stem to further standardize interpretation across institutions.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-007", "question": "A 63-year-old man with compensated cirrhosis (Child-Pugh A, MELD 9) has a 2.3-cm hepatocellular carcinoma (HCC) in segment VII adjacent to the right hepatic vein and diaphragm. He has portal hypertension with platelets 70,000/µL, small varices, and HVPG 13 mmHg. Liver function is preserved; he is not yet listed for transplant due to social issues. Which management offers the best balance of long-term oncologic control and hepatic reserve preservation?", "options": ["Open right posterior sectionectomy including segment VII and part of VIII", "Laparoscopic wedge resection of segment VII tumor with Pringle maneuver", "Ultrasound-guided percutaneous radiofrequency ablation (RFA) of the lesion", "Transarterial chemoembolization (TACE) followed by reassessment for ablation or resection", "Listing for liver transplantation without locoregional therapy until a donor becomes available"], "answer": "C", "answer_index": 2, "explanation": "For a solitary ≤3-cm HCC in a cirrhotic liver with significant portal hypertension and thrombocytopenia, percutaneous ablation achieves local control comparable to resection with lower risk of hepatic decompensation. Major or even limited resection (A, B) carries high risk in portal hypertension (HVPG >10 mmHg). TACE (D) is inferior to curative-intent ablation for small lesions. Delayed transplant without bridging (E) risks progression beyond criteria and prevents near-term curative local control.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 63-year-old with compensated cirrhosis (Child-Pugh A, MELD 9) but clinically significant portal hypertension (HVPG 13 mmHg, platelets 70,000/µL, varices), solitary 2.3-cm HCC in segment VII, not yet listed for transplant. Tumor ≤3 cm and solitary places him in very-early/early stage, potentially curable. Significant portal hypertension makes hepatic resection high risk for postoperative decompensation even with preserved synthetic function, so a parenchyma-sparing, non-resectional, curative modality is preferred. Percutaneous RFA is guideline-supported as first-line for solitary ≤3-cm HCC in cirrhotics with portal hypertension when transplant not immediately available.\\nOption appraisal: A and B (resection) are contraindicated/high risk given HVPG >10 mmHg and thrombocytopenia, despite small size. C (percutaneous RFA) offers curative-intent local therapy with better preservation of hepatic reserve. D (TACE) is palliative or bridging and inferior to ablation as primary curative therapy in small tumors. E (listing only) omits needed bridging/curative locoregional control and risks progression.\\nMain medical accuracy issues: None substantive; rationale is contemporary and consistent with BCLC/AASLD.\\nMinimal fix: Clarify that lesion location still permits technically feasible percutaneous ablation despite adjacency to diaphragm/right hepatic vein.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 63-year-old with compensated cirrhosis (Child-Pugh A, MELD 9) but clinically significant portal hypertension (HVPG 13 mmHg, platelets 70,000/µL, varices), solitary 2.3-cm HCC in segment VII, not yet listed for transplant. Tumor ≤3 cm and solitary places him in very-early/early stage, potentially curable. Significant portal hypertension makes hepatic resection high risk for postoperative decompensation even with preserved synthetic function, so a parenchyma-sparing, non-resectional, curative modality is preferred. Percutaneous RFA is guideline-supported as first-line for solitary ≤3-cm HCC in cirrhotics with portal hypertension when transplant not immediately available.\nOption appraisal: A and B (resection) are contraindicated/high risk given HVPG >10 mmHg and thrombocytopenia, despite small size. C (percutaneous RFA) offers curative-intent local therapy with better preservation of hepatic reserve. D (TACE) is palliative or bridging and inferior to ablation as primary curative therapy in small tumors. E (listing only) omits needed bridging/curative locoregional control and risks progression.\nMain medical accuracy issues: None substantive; rationale is contemporary and consistent with BCLC/AASLD.\nMinimal fix: Clarify that lesion location still permits technically feasible percutaneous ablation despite adjacency to diaphragm/right hepatic vein.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-008", "question": "A 39-year-old man presents with recurrent pancreatitis and is found to have a 2.5-cm enhancing mass in the pancreatic head that encases the intrapancreatic common bile duct, with upstream dilatation but no vascular involvement. EUS-FNA is nondiagnostic twice. CA 19-9 is normal. IgG4 level is mildly elevated at 180 mg/dL (ULN 135). CT shows a capsule-like rim around the lesion and diffuse, sausage-shaped enlargement of the gland. Which management approach is most appropriate?", "options": ["Trial of high-dose corticosteroids with close radiologic follow-up before considering surgery", "Pancreaticoduodenectomy because focal autoimmune pancreatitis cannot be reliably distinguished from adenocarcinoma", "Repeat EUS-FNA with core needle and flow cytometry to exclude lymphoma", "Observation alone with serial imaging in 6 months given low CA 19-9 and mild symptoms", "ERCP with biliary brushing cytology and stent placement, with surgery only if cytology is positive"], "answer": "A", "answer_index": 0, "explanation": "Imaging findings (capsule-like rim, sausage-shaped gland) and elevated IgG4 strongly suggest type 1 autoimmune pancreatitis; a steroid trial with close monitoring is accepted to avoid unnecessary Whipple when malignancy is not strongly supported. Immediate pancreaticoduodenectomy (B) is premature. Repeat biopsy (C) is less helpful given characteristic features. Observation alone (D) ignores ongoing pancreatitis and biliary obstruction. ERCP cytology (E) has low sensitivity and does not treat underlying inflammatory disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle-aged man with recurrent pancreatitis; 2.5‑cm enhancing pancreatic head lesion encasing intrapancreatic CBD, no vascular involvement; capsule-like rim; diffuse ‘sausage-shaped’ gland enlargement; mildly elevated IgG4; normal CA 19‑9; two nondiagnostic EUS‑FNAs. These imaging plus serology findings are classic for type 1 autoimmune pancreatitis, and repeated nondiagnostic biopsies reduce likelihood of adenocarcinoma but do not fully exclude it.\\nChoice A (steroid trial with close radiologic follow-up) aligns with accepted management in cases with high pretest probability of autoimmune pancreatitis and no high-risk features for cancer, to avoid unnecessary pancreaticoduodenectomy.\\nB is too aggressive given strong AIP indicators and lack of definitive evidence of malignancy. C is less appropriate because additional biopsy is unlikely to outperform the highly characteristic imaging/IgG4 pattern. D is unsafe/incorrect because patient has recurrent pancreatitis and obstructive features warranting active treatment. E overemphasizes ERCP cytology, which has low sensitivity and does not address the autoimmune process.\\nMain medical accuracy issues: None significant; approach reflects mainstream guidance.\\nMinimal fix: Explicitly state lack of concerning weight loss/jaundice or metastatic disease to further support a steroid trial as initial management.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle-aged man with recurrent pancreatitis; 2.5‑cm enhancing pancreatic head lesion encasing intrapancreatic CBD, no vascular involvement; capsule-like rim; diffuse ‘sausage-shaped’ gland enlargement; mildly elevated IgG4; normal CA 19‑9; two nondiagnostic EUS‑FNAs. These imaging plus serology findings are classic for type 1 autoimmune pancreatitis, and repeated nondiagnostic biopsies reduce likelihood of adenocarcinoma but do not fully exclude it.\nChoice A (steroid trial with close radiologic follow-up) aligns with accepted management in cases with high pretest probability of autoimmune pancreatitis and no high-risk features for cancer, to avoid unnecessary pancreaticoduodenectomy.\nB is too aggressive given strong AIP indicators and lack of definitive evidence of malignancy. C is less appropriate because additional biopsy is unlikely to outperform the highly characteristic imaging/IgG4 pattern. D is unsafe/incorrect because patient has recurrent pancreatitis and obstructive features warranting active treatment. E overemphasizes ERCP cytology, which has low sensitivity and does not address the autoimmune process.\nMain medical accuracy issues: None significant; approach reflects mainstream guidance.\nMinimal fix: Explicitly state lack of concerning weight loss/jaundice or metastatic disease to further support a steroid trial as initial management.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-009", "question": "A 26-year-old man presents with splenomegaly, hemoglobin 9.8 g/dL, platelets 130,000/µL, and leukocytes 5,200/µL. Peripheral smear shows tear-drop cells and leukoerythroblastosis. Bone marrow biopsy is markedly fibrotic with 1-2% blasts; JAK2, CALR, and MPL mutations are negative; next-generation sequencing reveals an isolated ASXL1 mutation. Cytogenetics are normal. He is transfusion independent but symptomatic from splenomegaly. DIPSS-plus score indicates intermediate-2 risk primary myelofibrosis. His 10/10 HLA-matched sibling donor is available. Which is the most appropriate management strategy?", "options": ["Begin ruxolitinib and defer allogeneic stem cell transplantation until he becomes transfusion dependent", "Proceed to allogeneic stem cell transplantation in first chronic phase despite triple-negative driver status", "Observation with serial monitoring; ASXL1 mutation alone does not justify early transplant", "Splenectomy followed by hydroxyurea cytoreduction to delay transplantation", "Ruxolitinib bridge therapy for 3-6 months to reduce spleen size, then proceed to planned allogeneic transplantation"], "answer": "E", "answer_index": 4, "explanation": "Intermediate-2 risk myelofibrosis in a young patient with an available donor warrants allogeneic transplant; bridging with ruxolitinib can reduce spleen size and improve conditioning tolerance without compromising transplant timing. Deferring transplant (A, C) risks disease progression. Splenectomy (D) before transplant is reserved for select cases due to morbidity. Immediate transplant without JAK inhibitor optimization (B) may lead to worse peri-transplant outcomes in massively enlarged spleens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 26-year-old (very young), primary myelofibrosis (fibrotic marrow, leukoerythroblastosis, tear-drop cells), triple-negative for JAK2/CALR/MPL with isolated ASXL1 mutation (adverse), DIPSS-plus intermediate-2 risk, symptomatic splenomegaly, transfusion independent, normal cytogenetics, and an available 10/10 HLA-matched sibling donor.\\nThese features strongly support proceeding to allogeneic HSCT in first chronic phase; in current practice, ruxolitinib pre-transplant (3–6 months) to reduce spleen size and improve performance/conditioning tolerance is standard, making option E the single best answer.\\nOption A inappropriately delays HSCT until transfusion dependence, contrary to guideline-based risk-adapted early transplant for intermediate-2 young patients. Option B omits JAK inhibitor optimization in the setting of symptomatic massive spleen. Option C ignores both intermediate-2 risk and adverse ASXL1 mutation. Option D splenectomy is high-risk and reserved for select situations, not first-line strategy.\\nNo internal contradictions; data provided is sufficient for a unique best choice and key matches that choice.\\nMinimal fix: Explicitly state spleen is “massively enlarged” or give spleen size to further justify JAK inhibitor debulking before HSCT, aligning directly with the explanation’s wording.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 26-year-old (very young), primary myelofibrosis (fibrotic marrow, leukoerythroblastosis, tear-drop cells), triple-negative for JAK2/CALR/MPL with isolated ASXL1 mutation (adverse), DIPSS-plus intermediate-2 risk, symptomatic splenomegaly, transfusion independent, normal cytogenetics, and an available 10/10 HLA-matched sibling donor.\nThese features strongly support proceeding to allogeneic HSCT in first chronic phase; in current practice, ruxolitinib pre-transplant (3–6 months) to reduce spleen size and improve performance/conditioning tolerance is standard, making option E the single best answer.\nOption A inappropriately delays HSCT until transfusion dependence, contrary to guideline-based risk-adapted early transplant for intermediate-2 young patients. Option B omits JAK inhibitor optimization in the setting of symptomatic massive spleen. Option C ignores both intermediate-2 risk and adverse ASXL1 mutation. Option D splenectomy is high-risk and reserved for select situations, not first-line strategy.\nNo internal contradictions; data provided is sufficient for a unique best choice and key matches that choice.\nMinimal fix: Explicitly state spleen is “massively enlarged” or give spleen size to further justify JAK inhibitor debulking before HSCT, aligning directly with the explanation’s wording.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-010", "question": "A 31-year-old woman with systemic lupus erythematosus, class IV lupus nephritis, and high-titer anti-dsDNA presents with a 4-week history of progressive symmetric lower extremity weakness, areflexia, and sensory loss. NCS/EMG show a demyelinating polyneuropathy consistent with CIDP. She is on prednisone 10 mg daily and hydroxychloroquine. Creatinine is 1.3 mg/dL; she has nephrotic-range proteinuria. Which immunologic treatment strategy best balances disease control and long-term toxicity?", "options": ["High-dose IV methylprednisolone pulses followed by oral prednisone 1 mg/kg for both CIDP and lupus nephritis", "IVIG monthly for CIDP plus increase prednisone to 0.5 mg/kg, with no other agents", "Rituximab-based regimen targeting both CIDP and lupus nephritis with tapering of steroids", "Cyclophosphamide induction followed by azathioprine maintenance for lupus and CIDP", "Plasma exchange for CIDP plus mycophenolate mofetil for lupus nephritis"], "answer": "C", "answer_index": 2, "explanation": "Rituximab has efficacy in both CIDP (especially autoimmune-mediated forms) and proliferative lupus nephritis, allowing steroid sparing and addressing shared B-cell pathogenesis. High-dose steroids alone (A, B) worsen long-term toxicity and may be insufficient for nephritis. Cyclophosphamide (D) carries more gonadal and malignancy risk in a young woman. Plasmapheresis (E) gives transient CIDP benefit but does not control chronic B-cell-driven lupus nephritis as effectively as rituximab-based regimens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman (31) with SLE, class IV lupus nephritis, active serologies (high-titer anti-dsDNA), nephrotic-range proteinuria, and a new chronic demyelinating polyneuropathy (CIDP) needing long-term immunomodulation. Current regimen is only low-dose prednisone and hydroxychloroquine; question explicitly asks for a strategy that “best balances disease control and long-term toxicity.”\\nRationale for C: Rituximab addresses B‑cell–mediated pathology in both CIDP and proliferative lupus nephritis and is steroid-sparing, making it optimal for a young woman where cumulative glucocorticoid and alkylator toxicity are major concerns.\\nWhy others are worse: A and B rely on high/moderate-dose chronic steroids without additional steroid-sparing nephritis therapy—poor long-term toxicity profile and inadequate for class IV nephritis. D (cyclophosphamide) is effective for nephritis but has significant gonadal and malignancy risk in a 31-year-old and is not standard first-line for CIDP. E combines a transient CIDP treatment (plasmapheresis) with mycophenolate, which is good for nephritis but does not directly address CIDP long-term.\\nMain medical accuracy issues: Minor—rituximab for CIDP is off-label but evidence-supported; this nuance is acceptable for boards. \\nMinimal fix: Explicitly note “evidence-supported off-label use of rituximab for CIDP” in the explanation, not the stem, to clarify context for learners.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman (31) with SLE, class IV lupus nephritis, active serologies (high-titer anti-dsDNA), nephrotic-range proteinuria, and a new chronic demyelinating polyneuropathy (CIDP) needing long-term immunomodulation. Current regimen is only low-dose prednisone and hydroxychloroquine; question explicitly asks for a strategy that “best balances disease control and long-term toxicity.”\nRationale for C: Rituximab addresses B‑cell–mediated pathology in both CIDP and proliferative lupus nephritis and is steroid-sparing, making it optimal for a young woman where cumulative glucocorticoid and alkylator toxicity are major concerns.\nWhy others are worse: A and B rely on high/moderate-dose chronic steroids without additional steroid-sparing nephritis therapy—poor long-term toxicity profile and inadequate for class IV nephritis. D (cyclophosphamide) is effective for nephritis but has significant gonadal and malignancy risk in a 31-year-old and is not standard first-line for CIDP. E combines a transient CIDP treatment (plasmapheresis) with mycophenolate, which is good for nephritis but does not directly address CIDP long-term.\nMain medical accuracy issues: Minor—rituximab for CIDP is off-label but evidence-supported; this nuance is acceptable for boards. \nMinimal fix: Explicitly note “evidence-supported off-label use of rituximab for CIDP” in the explanation, not the stem, to clarify context for learners.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-011", "question": "A 27-year-old woman sustains a severe crush-avulsion injury to her dominant right forearm in an industrial press. There is segmental loss of the ulnar artery, ulnar nerve (6 cm gap at the wrist), and extensive soft-tissue loss over the volar-ulnar forearm with exposed flexor tendons; radial artery and median nerve are intact. Hand perfusion is marginal via the radial artery. Debridement leaves a 12 × 8 cm wound and nonrepairable FDS/FDP to ring and small fingers. Considering function and reconstructive ladder, what is the optimal reconstructive strategy in a single stage?", "options": ["Local rotational fasciocutaneous flap with reversed interpositional saphenous vein graft for ulnar artery and autologous sural nerve cable grafts for ulnar nerve", "Free anterolateral thigh (ALT) flap with flow-through reconstruction of the ulnar artery and nerve coaptation via sural nerve graft", "Split-thickness skin graft over the exposed tendons after tendon shortening and radial artery-only perfusion", "Pedicled groin flap for soft-tissue coverage and delayed ulnar nerve grafting once the wound bed is stable", "Free radial forearm flap from the contralateral limb including cephalic vein for venous outflow and ulnar nerve primary end-to-end repair under tension"], "answer": "B", "answer_index": 1, "explanation": "A free ALT flap can provide robust soft-tissue coverage and can be configured as a flow-through flap to reconstitute the ulnar artery while allowing concurrent ulnar nerve cable grafting, optimizing perfusion and nerve regeneration in one stage. Local rotational flaps (A) are insufficient for the large defect and lack flow-through capabilities. Skin graft alone (C) is inadequate over exposed tendons and does not restore artery/nerve. Staged groin flap (D) delays nerve repair. A contralateral radial forearm flap (E) sacrifices a major artery and cannot provide tension-free primary nerve repair.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman; dominant forearm; large 12×8 cm volar-ulnar soft-tissue defect with exposed flexor tendons; segmental loss of ulnar artery and 6‑cm ulnar nerve gap; marginal perfusion via radial artery alone; nonrepairable FDS/FDP to ring/small; question explicitly asks for optimal single‑stage reconstruction considering function and reconstructive ladder.\\nChoice B (free ALT flow‑through flap with ulnar artery reconstruction and simultaneous ulnar nerve grafting) best addresses: (1) large, complex defect; (2) need for durable, vascularized coverage over tendons; (3) revascularization of ulnar artery; (4) timely nerve reconstruction in one stage.\\nOption A: local fasciocutaneous flap unlikely to cover 12×8 cm, and no flow‑through arterial reconstruction; poorer reliability in this setting. C: STSG over bare tendons and no artery/nerve restoration is clearly inadequate. D: staged pedicled groin flap delays nerve repair and offers inferior functional outcome versus immediate free flap. E: sacrifices contralateral radial artery and proposes primary end‑to‑end repair over a 6‑cm gap (not feasible tension‑free).\\nMedical accuracy: Management principles and critique of alternatives are consistent with contemporary reconstructive practice.\\nMinimal fix: Specify that local tissue availability is limited (e.g., “no local fasciocutaneous flap could reliably cover the 12×8 cm defect”) to strengthen exclusion of option A.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman; dominant forearm; large 12×8 cm volar-ulnar soft-tissue defect with exposed flexor tendons; segmental loss of ulnar artery and 6‑cm ulnar nerve gap; marginal perfusion via radial artery alone; nonrepairable FDS/FDP to ring/small; question explicitly asks for optimal single‑stage reconstruction considering function and reconstructive ladder.\nChoice B (free ALT flow‑through flap with ulnar artery reconstruction and simultaneous ulnar nerve grafting) best addresses: (1) large, complex defect; (2) need for durable, vascularized coverage over tendons; (3) revascularization of ulnar artery; (4) timely nerve reconstruction in one stage.\nOption A: local fasciocutaneous flap unlikely to cover 12×8 cm, and no flow‑through arterial reconstruction; poorer reliability in this setting. C: STSG over bare tendons and no artery/nerve restoration is clearly inadequate. D: staged pedicled groin flap delays nerve repair and offers inferior functional outcome versus immediate free flap. E: sacrifices contralateral radial artery and proposes primary end‑to‑end repair over a 6‑cm gap (not feasible tension‑free).\nMedical accuracy: Management principles and critique of alternatives are consistent with contemporary reconstructive practice.\nMinimal fix: Specify that local tissue availability is limited (e.g., “no local fasciocutaneous flap could reliably cover the 12×8 cm defect”) to strengthen exclusion of option A.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-012", "question": "A 54-year-old man with a 2.2-cm pituitary macroadenoma causing acromegaly undergoes endoscopic endonasal resection. Postoperative day 1 labs show serum sodium 142 mmol/L and urine output 3.5 L/day. On day 7, sodium is 128 mmol/L with serum osmolality 265 mOsm/kg and urine osmolality 600 mOsm/kg; he is clinically euvolemic. Morning cortisol is 15 µg/dL. On day 12, sodium falls to 118 mmol/L despite fluid restriction, and he becomes confused; serum osmolality 250 mOsm/kg, urine osmolality 750 mOsm/kg. MRI shows no new findings. Which mechanism best explains this delayed worsening hyponatremia?", "options": ["Persistent syndrome of inappropriate antidiuretic hormone secretion (SIADH) from hypothalamic neuronal injury", "Triphasic water balance disorder with transition from SIADH phase to late-phase permanent diabetes insipidus", "Cerebral salt wasting due to subclinical subarachnoid hemorrhage during surgery", "Reset osmostat due to chronic hyponatremia from preoperative growth hormone excess", "Glucocorticoid deficiency from delayed postoperative hypopituitarism"], "answer": "A", "answer_index": 0, "explanation": "The typical triphasic pattern after pituitary surgery is early DI, then SIADH-related hyponatremia around days 5-10; persistent, severe, euvolemic hyponatremia with high urine osmolality is most consistent with sustained SIADH. Transition to DI (B) would cause hypernatremia and dilute urine. Cerebral salt wasting (C) would show hypovolemia and high urine sodium but is rare here. Reset osmostat (D) would not present with acute confusion at Na 118. Cortisol deficiency (E) is unlikely with normal morning cortisol.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Post–pituitary surgery course with (1) early high urine output (~3.5 L/day) and normal Na, consistent with an initial DI phase; (2) day 7 hyponatremia (Na 128) with low serum osmolality, inappropriately high urine osmolality (600 mOsm/kg), and clinical euvolemia; (3) further drop in sodium to 118 by day 12 despite fluid restriction, with persistently high urine osmolality (750 mOsm/kg) and no new MRI findings; (4) normal morning cortisol (15 µg/dL). This pattern matches the SIADH phase of the classic triphasic water-balance disorder after pituitary surgery, with persistent inappropriate ADH secretion.\\nOption analysis: A correctly describes persistent SIADH from hypothalamic injury. B is incompatible with continued hyponatremia and concentrated urine (late DI would cause hypernatremia and dilute urine). C would require hypovolemia and high urine sodium, which are not described and is rare in this setting. D (reset osmostat) doesn’t fit the acute, symptomatic, progressing hyponatremia. E is countered by the normal cortisol value.\\nMain medical accuracy issues: None significant; pattern and explanations are aligned with standard neurosurgical/endocrine teaching.\\nMinimal fix: Add explicit urine sodium (e.g., >40 mmol/L) to strengthen SIADH characterization, though not strictly necessary.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Post–pituitary surgery course with (1) early high urine output (~3.5 L/day) and normal Na, consistent with an initial DI phase; (2) day 7 hyponatremia (Na 128) with low serum osmolality, inappropriately high urine osmolality (600 mOsm/kg), and clinical euvolemia; (3) further drop in sodium to 118 by day 12 despite fluid restriction, with persistently high urine osmolality (750 mOsm/kg) and no new MRI findings; (4) normal morning cortisol (15 µg/dL). This pattern matches the SIADH phase of the classic triphasic water-balance disorder after pituitary surgery, with persistent inappropriate ADH secretion.\nOption analysis: A correctly describes persistent SIADH from hypothalamic injury. B is incompatible with continued hyponatremia and concentrated urine (late DI would cause hypernatremia and dilute urine). C would require hypovolemia and high urine sodium, which are not described and is rare in this setting. D (reset osmostat) doesn’t fit the acute, symptomatic, progressing hyponatremia. E is countered by the normal cortisol value.\nMain medical accuracy issues: None significant; pattern and explanations are aligned with standard neurosurgical/endocrine teaching.\nMinimal fix: Add explicit urine sodium (e.g., >40 mmol/L) to strengthen SIADH characterization, though not strictly necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-013", "question": "A 69-year-old man with T2N0M0 glottic squamous cell carcinoma extending to the anterior commissure is planned for definitive radiotherapy. He is a heavy smoker with severe COPD and cannot tolerate prolonged immobilization. The radiation oncologist must choose the optimal fractionation regimen to maximize local control while minimizing acute laryngeal edema and long-term dysphagia. Which regimen best balances these goals?", "options": ["Conventional 2.0 Gy per fraction to 70 Gy over 7 weeks", "Hypofractionated 2.25 Gy per fraction to 63 Gy over 5.6 weeks", "Hyperfractionated 1.2 Gy twice daily to 79.2 Gy total dose", "Concomitant boost regimen with 1.8 Gy daily plus 1.5 Gy second daily fraction in the final 3 weeks", "Stereotactic body radiotherapy (SBRT) 7.5 Gy × 5 fractions to the glottic larynx"], "answer": "B", "answer_index": 1, "explanation": "For early to select T2 glottic cancers, modest hypofractionation (e.g., 2.25 Gy/fraction to ~63 Gy) improves local control with acceptable toxicity and shorter overall treatment time, particularly useful in patients with limited tolerance for prolonged immobilization. Conventional fractionation (A) is effective but less optimal in control and time. Hyperfractionation (C) and concomitant boost (D) increase mucosal toxicity. SBRT (E) for glottic cancer remains investigational with concerns about cartilage necrosis and voice quality.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: T2N0M0 glottic SCC involving anterior commissure; planned definitive RT; patient has severe COPD and cannot tolerate prolonged immobilization; goal is to maximize local control while minimizing acute laryngeal edema and long-term dysphagia and to shorten treatment duration. Early (T1–selected T2) glottic cancers are well supported in the literature to benefit from modest hypofractionation (≈2.25 Gy/fx to ~63 Gy) with improved local control and similar or acceptable toxicity versus 2.0 Gy/fx, and it shortens overall treatment time—important for this patient’s limited tolerance. Thus option B is the best balance.\\nOption A: longer overall time, slightly inferior local control in T2, not exploiting hypofractionation advantage. C and D (hyperfractionation/concomitant boost) are associated with greater acute mucosal toxicity and do not address the immobilization constraint. E (SBRT) is still largely investigational in this setting, with concerns for cartilage damage and functional outcomes.\\nNo major logical gaps or contradictions; the stem provides sufficient detail to identify a single best regimen.\\nMinimal fix: Explicitly state this is an early-stage glottic carcinoma where modest hypofractionation is standard-of-care (e.g., “Early T1–T2 glottic cancer”) to align fully with guideline phrasing.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: T2N0M0 glottic SCC involving anterior commissure; planned definitive RT; patient has severe COPD and cannot tolerate prolonged immobilization; goal is to maximize local control while minimizing acute laryngeal edema and long-term dysphagia and to shorten treatment duration. Early (T1–selected T2) glottic cancers are well supported in the literature to benefit from modest hypofractionation (≈2.25 Gy/fx to ~63 Gy) with improved local control and similar or acceptable toxicity versus 2.0 Gy/fx, and it shortens overall treatment time—important for this patient’s limited tolerance. Thus option B is the best balance.\nOption A: longer overall time, slightly inferior local control in T2, not exploiting hypofractionation advantage. C and D (hyperfractionation/concomitant boost) are associated with greater acute mucosal toxicity and do not address the immobilization constraint. E (SBRT) is still largely investigational in this setting, with concerns for cartilage damage and functional outcomes.\nNo major logical gaps or contradictions; the stem provides sufficient detail to identify a single best regimen.\nMinimal fix: Explicitly state this is an early-stage glottic carcinoma where modest hypofractionation is standard-of-care (e.g., “Early T1–T2 glottic cancer”) to align fully with guideline phrasing.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-014", "question": "A 60-year-old man with severe COPD (FEV1 30% predicted) undergoes right pneumonectomy for central squamous cell carcinoma. On postoperative day 3 he develops sudden respiratory distress, hypotension, and jugular venous distention. CXR shows mediastinal shift toward the left (remaining lung side) with hyperinflation and flattened diaphragm. Emergent bronchoscopy reveals no mucus plug. Echocardiogram shows right ventricular dilation and compression of the left atrium. Which is the most likely diagnosis?", "options": ["Postpneumonectomy pulmonary edema of the remaining lung", "Early bronchopleural fistula with tension pneumothorax on the pneumonectomy side", "Acute pulmonary embolism to the left pulmonary artery", "Postpneumonectomy syndrome due to mediastinal shift and bronchial kinking", "Cardiac tamponade from postoperative hemopericardium"], "answer": "D", "answer_index": 3, "explanation": "Postpneumonectomy syndrome is due to excessive mediastinal shift causing kinking/compression of the remaining main bronchus and cardiovascular structures; though classically delayed, it can present early with hyperinflation of the remaining lung and mediastinal shift toward it, leading to RV dilation and LA compression. Pulmonary edema (A) would not explain marked mediastinal shift. Tension pneumothorax on the pneumonectomy side (B) would shift mediastinum away from the remaining lung. Massive PE (C) lacks imaging features of overinflation and shift. Tamponade (E) shows equal chamber pressures but not lung overinflation or shift.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent right pneumonectomy; abrupt respiratory distress with hypotension and JVD; CXR showing mediastinal shift toward the remaining (left) lung with hyperinflation and flattened diaphragm; bronchoscopy without obstruction; echocardiogram with RV dilation and left atrial compression. These findings together indicate excessive mediastinal shift with compression of airway and cardiac structures after pneumonectomy, i.e., postpneumonectomy syndrome.\\nOption analysis: A (postpneumonectomy pulmonary edema) would cause diffuse infiltrates in the remaining lung, not mediastinal shift with hyperinflation. B (bronchopleural fistula with tension pneumothorax) on the pneumonectomy side would shift the mediastinum away from the remaining lung. C (acute PE) can cause RV dilation but does not explain unilateral hyperinflation with mediastinal shift toward that side. E (cardiac tamponade) would explain hypotension/JVD but not overinflated remaining lung or mediastinal shift pattern.\\nMain medical accuracy issue(s): Postpneumonectomy syndrome is classically delayed, but early presentation is rare yet plausible; this is an acceptable nuance, not an error.\\nMinimal fix: Add “several days after surgery” or “progressive” to underscore that this is an early but not immediate postoperative complication and reinforce the temporal association with mediastinal shift and hyperinflation.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent right pneumonectomy; abrupt respiratory distress with hypotension and JVD; CXR showing mediastinal shift toward the remaining (left) lung with hyperinflation and flattened diaphragm; bronchoscopy without obstruction; echocardiogram with RV dilation and left atrial compression. These findings together indicate excessive mediastinal shift with compression of airway and cardiac structures after pneumonectomy, i.e., postpneumonectomy syndrome.\nOption analysis: A (postpneumonectomy pulmonary edema) would cause diffuse infiltrates in the remaining lung, not mediastinal shift with hyperinflation. B (bronchopleural fistula with tension pneumothorax) on the pneumonectomy side would shift the mediastinum away from the remaining lung. C (acute PE) can cause RV dilation but does not explain unilateral hyperinflation with mediastinal shift toward that side. E (cardiac tamponade) would explain hypotension/JVD but not overinflated remaining lung or mediastinal shift pattern.\nMain medical accuracy issue(s): Postpneumonectomy syndrome is classically delayed, but early presentation is rare yet plausible; this is an acceptable nuance, not an error.\nMinimal fix: Add “several days after surgery” or “progressive” to underscore that this is an early but not immediate postoperative complication and reinforce the temporal association with mediastinal shift and hyperinflation.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-015", "question": "A 67-year-old woman with lifestyle-limiting claudication and rest pain in the right foot has an occluded right common iliac artery and diffuse calcific disease of the ipsilateral external iliac and common femoral arteries. The left iliac system is patent with a prior kissing stent at the aortic bifurcation. Coronary disease and frailty preclude aortobifemoral bypass. Which revascularization option best optimizes long-term patency and limb salvage?", "options": ["Right axillo-femoral bypass using an 8-mm ringed PTFE graft to the common femoral artery", "Endovascular recanalization and stenting of the occluded right common iliac plus external iliac angioplasty", "Femoral-femoral crossover bypass from left common femoral artery to right profunda femoris artery with endarterectomy of the right common femoral", "Endovascular iliac recanalization combined with drug-coated balloon angioplasty of the common femoral artery", "Ilio-femoral bypass from left common iliac artery to right common femoral artery via a retroperitoneal route"], "answer": "C", "answer_index": 2, "explanation": "Given a hostile aorta and existing left iliac stent, fem-fem crossover with CFA endarterectomy to the profunda provides robust inflow and durable outflow while avoiding major aortic surgery. Axillo-femoral bypass (A) has lower long-term patency. Pure endovascular recanalization (B, D) may be limited by heavy CFA calcification and restenosis risk, and CFA is a poor stent target. Ilio-femoral bypass (E) is more invasive and may be technically challenging given the prior kissing stent and comorbidities.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Severe, limb‑threatening ischemia (rest pain) of right leg; right common iliac occluded; diffuse calcific disease of right external iliac and common femoral; left iliac system patent but already stented at aortic bifurcation; aortobifemoral bypass contraindicated because of coronary disease/frailty; goal is best long‑term patency and limb salvage.\\n\\nBest interpretation: Durable extra‑anatomic inflow from the good left side with optimized profunda outflow is preferred over higher‑failure axillo‑femoral bypass and over complex endovascular approaches in a heavily calcified CFA (a poor stent target). Thus femoral–femoral crossover from left CFA to right profunda with CFA endarterectomy (C) is the most defensible.\\n\\nOther options: (A) Axillo‑femoral grafts have clearly worse long‑term patency. (B) and (D) rely on endovascular treatment across a heavily calcified CFA and diseased iliac segment, with relatively poor durability and technical concerns for CFA stenting. (E) Ilio‑femoral bypass traversing prior kissing stent and retroperitoneal exposure is more invasive with higher risk in a frail, coronary‑diseased patient.\\n\\nMinimal fix: Explicitly state that the patient is a poor candidate for extensive retroperitoneal/iliac reconstruction, reinforcing the preference for extra‑anatomic fem‑fem bypass plus CFA endarterectomy for durability and limb salvage.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Severe, limb‑threatening ischemia (rest pain) of right leg; right common iliac occluded; diffuse calcific disease of right external iliac and common femoral; left iliac system patent but already stented at aortic bifurcation; aortobifemoral bypass contraindicated because of coronary disease/frailty; goal is best long‑term patency and limb salvage.\n\nBest interpretation: Durable extra‑anatomic inflow from the good left side with optimized profunda outflow is preferred over higher‑failure axillo‑femoral bypass and over complex endovascular approaches in a heavily calcified CFA (a poor stent target). Thus femoral–femoral crossover from left CFA to right profunda with CFA endarterectomy (C) is the most defensible.\n\nOther options: (A) Axillo‑femoral grafts have clearly worse long‑term patency. (B) and (D) rely on endovascular treatment across a heavily calcified CFA and diseased iliac segment, with relatively poor durability and technical concerns for CFA stenting. (E) Ilio‑femoral bypass traversing prior kissing stent and retroperitoneal exposure is more invasive with higher risk in a frail, coronary‑diseased patient.\n\nMinimal fix: Explicitly state that the patient is a poor candidate for extensive retroperitoneal/iliac reconstruction, reinforcing the preference for extra‑anatomic fem‑fem bypass plus CFA endarterectomy for durability and limb salvage.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-016", "question": "A 58-year-old man with a 3.8-cm right thyroid nodule and compressive symptoms undergoes total thyroidectomy. Final pathology shows a 3.8-cm encapsulated follicular-patterned lesion with capsular and focal vascular invasion in 2 of 8 intracapsular vessels, RAS-mutant, no extrathyroidal extension, and no lymph node involvement. According to modern risk stratification and evolving nomenclature, which postoperative management is most appropriate?", "options": ["Classify as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and no further therapy", "Classify as minimally invasive follicular thyroid carcinoma and recommend routine radioactive iodine ablation", "Classify as encapsulated angioinvasive follicular variant papillary thyroid carcinoma and consider RAI only if postoperative thyroglobulin is detectable", "Classify as low-risk differentiated thyroid carcinoma managed with levothyroxine to keep TSH mildly suppressed and no routine RAI", "Classify as high-risk due to vascular invasion and treat with high-dose RAI and aggressive TSH suppression (<0.1 mIU/L)"], "answer": "D", "answer_index": 3, "explanation": "Encapsulated follicular-patterned tumors with limited vascular invasion (≤4 foci) and no extrathyroidal extension are considered low-risk differentiated thyroid carcinomas; current guidelines favor TSH suppression and no routine RAI, particularly in RAS-mutated lesions without nodal disease. NIFTP (A) requires no invasion; this lesion shows both capsular and vascular invasion. Routine RAI (B, E) is excessive for low-risk tumors. Labeling as high-risk (E) is not justified by limited angioinvasion alone. Option C misclassifies the entity and overemphasizes histologic subtype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3.8‑cm encapsulated follicular‑patterned lesion; capsular and focal vascular invasion in 2/8 intracapsular vessels; no extrathyroidal extension; no nodal disease; RAS‑mutant. These features define an encapsulated follicular‑patterned differentiated thyroid carcinoma with limited angioinvasion (≤4 foci), which current ATA and contemporary literature classify as low‑risk, with low recurrence and mortality. Postoperative management for low‑risk DTC typically includes levothyroxine with mild TSH suppression and no routine RAI after total thyroidectomy.\\nOption D directly reflects this approach and does not hinge on the exact histologic label, only on risk category and management. A is incorrect because NIFTP requires noninvasive architecture—no capsular or vascular invasion. B and E over-treat by recommending routine/high‑dose RAI and aggressive suppression for a low‑risk tumor. C misclassifies the tumor and still implies RAI consideration when not usually needed in clearly low‑risk disease.\\nMain medical accuracy issue(s): None material; the risk stratification and management are consistent with current standards. Minimal fix: Explicitly name the entity as “encapsulated follicular-patterned DTC with limited angioinvasion” in the stem to avoid any nomenclature ambiguity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3.8‑cm encapsulated follicular‑patterned lesion; capsular and focal vascular invasion in 2/8 intracapsular vessels; no extrathyroidal extension; no nodal disease; RAS‑mutant. These features define an encapsulated follicular‑patterned differentiated thyroid carcinoma with limited angioinvasion (≤4 foci), which current ATA and contemporary literature classify as low‑risk, with low recurrence and mortality. Postoperative management for low‑risk DTC typically includes levothyroxine with mild TSH suppression and no routine RAI after total thyroidectomy.\nOption D directly reflects this approach and does not hinge on the exact histologic label, only on risk category and management. A is incorrect because NIFTP requires noninvasive architecture—no capsular or vascular invasion. B and E over-treat by recommending routine/high‑dose RAI and aggressive suppression for a low‑risk tumor. C misclassifies the tumor and still implies RAI consideration when not usually needed in clearly low‑risk disease.\nMain medical accuracy issue(s): None material; the risk stratification and management are consistent with current standards. Minimal fix: Explicitly name the entity as “encapsulated follicular-patterned DTC with limited angioinvasion” in the stem to avoid any nomenclature ambiguity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-017", "question": "A 66-year-old man with long-standing diabetes and peripheral neuropathy presents with chronic mesenteric ischemia symptoms and weight loss. CTA shows high-grade stenoses of both the celiac and superior mesenteric arteries (SMA) with a patent inferior mesenteric artery and extensive collateralization. There is a focal 2.5-cm jejunal stricture with mild upstream dilation but no mass. Intraoperatively, the bowel is patchy but viable; the stricture is firm and fibrotic. Biopsy shows transmural fibrosis without active vasculitis. Which strategy best addresses both symptoms and long-term gut viability?", "options": ["Endovascular stenting of SMA only, leaving celiac stenosis untreated", "Open antegrade aorto-SMA bypass plus segmental resection of the jejunal stricture", "Isolated resection of the jejunal stricture without mesenteric revascularization", "Retrograde iliac-to-SMA bypass only, with no bowel resection to avoid short-bowel risk", "Endovascular stenting of both celiac and SMA followed by observation of the stricture"], "answer": "B", "answer_index": 1, "explanation": "Symptomatic chronic mesenteric ischemia with structural fibrotic jejunal stricture requires both durable inflow restoration and removal of the fixed lesion; open aorto-SMA bypass offers superior long-term patency in multivessel disease, and resection treats the fibrotic stricture. SMA-only stenting (A) or dual-vessel stenting (E) may have higher restenosis and do not resolve fixed fibrosis. Resection alone (C) ignores global ischemia. Retrograde iliac-SMA bypass without resection (D) leaves a mechanical obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 66-year-old man with classic chronic mesenteric ischemia (postprandial pain, weight loss), CTA showing high-grade celiac and SMA stenoses with collaterals, a focal 2.5-cm jejunal fibrotic stricture, intraoperative finding of patchy but viable bowel, and biopsy-confirmed transmural fibrosis without active vasculitis. This indicates both global low-flow ischemia and a fixed, structurally narrowed segment.\\nOption B—open antegrade aorto-SMA bypass plus segmental resection—best provides durable mesenteric inflow (gold-standard open bypass in multivessel chronic mesenteric ischemia) and removes the nonreversible fibrotic stricture, directly addressing symptoms and long-term viability. \\nA (SMA stent only) leaves celiac disease untreated and has higher restenosis risk; E (dual-vessel stenting) improves flow but leaves the fixed fibrotic stricture, so symptoms/obstruction may persist. C (resection alone) ignores diffuse mesenteric ischemia and jeopardizes future gut viability. D (retrograde iliac–SMA bypass only) improves flow but leaves a mechanical obstruction.\\nNo internal contradictions or equally strong alternatives; bypass-plus-resection is clearly superior.\\nMinimal fix: Explicitly state that the patient is a good surgical candidate to pre-empt debates about endovascular-first strategy in high-risk patients.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 66-year-old man with classic chronic mesenteric ischemia (postprandial pain, weight loss), CTA showing high-grade celiac and SMA stenoses with collaterals, a focal 2.5-cm jejunal fibrotic stricture, intraoperative finding of patchy but viable bowel, and biopsy-confirmed transmural fibrosis without active vasculitis. This indicates both global low-flow ischemia and a fixed, structurally narrowed segment.\nOption B—open antegrade aorto-SMA bypass plus segmental resection—best provides durable mesenteric inflow (gold-standard open bypass in multivessel chronic mesenteric ischemia) and removes the nonreversible fibrotic stricture, directly addressing symptoms and long-term viability. \nA (SMA stent only) leaves celiac disease untreated and has higher restenosis risk; E (dual-vessel stenting) improves flow but leaves the fixed fibrotic stricture, so symptoms/obstruction may persist. C (resection alone) ignores diffuse mesenteric ischemia and jeopardizes future gut viability. D (retrograde iliac–SMA bypass only) improves flow but leaves a mechanical obstruction.\nNo internal contradictions or equally strong alternatives; bypass-plus-resection is clearly superior.\nMinimal fix: Explicitly state that the patient is a good surgical candidate to pre-empt debates about endovascular-first strategy in high-risk patients.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-018", "question": "A 52-year-old woman with a history of Roux-en-Y gastric bypass 8 years ago presents with refractory iron-deficiency anemia and vague postprandial epigastric pain. EGD and colonoscopy are negative. Capsule endoscopy shows a circumferential, friable lesion in the excluded stomach. CT enterography confirms a 3.5-cm mass in the excluded gastric remnant without metastatic disease. Which surgical approach is most appropriate for oncologic control and access limitations?", "options": ["Laparoscopic transgastric gastroscopy through the gastric pouch with submucosal dissection of the lesion", "Laparoscopic-assisted resection of the excluded stomach mass via gastrotomy in the remnant and wedge resection", "Conversion of the Roux-en-Y gastric bypass to normal anatomy followed by subtotal gastrectomy", "Open completion gastrectomy including the excluded stomach with Roux-en-Y esophagojejunostomy", "Endoscopic ultrasound-guided radiofrequency ablation of the mass via transluminal puncture from the alimentary limb"], "answer": "D", "answer_index": 3, "explanation": "A 3.5-cm circumferential, friable mass in the excluded stomach is highly suspicious for carcinoma; completion gastrectomy provides oncologic resection with appropriate lymphadenectomy, best achieved via open approach given altered anatomy and access. Laparoscopic wedge resection (B) is inadequate for circumferential malignancy. Converting anatomy first (C) adds complexity without oncologic benefit. Transgastric endoscopic resection (A) and RFA (E) are inappropriate for likely invasive carcinoma in an excluded segment.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Prior Roux-en-Y gastric bypass with an inaccessible excluded stomach; refractory iron-deficiency anemia and epigastric pain; capsule endoscopy and CT show a 3.5-cm circumferential, friable lesion/mass in the excluded gastric remnant; no metastatic disease; question explicitly asks for the most appropriate surgical approach considering oncologic control and access limitations.\\nThese findings make gastric carcinoma of the excluded remnant highly likely and require oncologic resection with lymphadenectomy and reliable margin control. Open completion gastrectomy including the excluded stomach with Roux-en-Y esophagojejunostomy (D) is the most defensible option, addressing both malignancy and altered anatomy.\\nOption A (transgastric endoscopic submucosal dissection) and E (EUS-guided RFA) are inappropriate for suspected invasive cancer in an excluded segment and are non-oncologic. B (laparoscopic wedge resection) is inadequate for a circumferential lesion and proper lymphadenectomy. C (conversion to normal anatomy followed by subtotal gastrectomy) adds unnecessary complexity without oncologic advantage over a direct completion gastrectomy.\\nMain medical accuracy issues: none significant; rationale is consistent with standard surgical oncology practice. Minimal fix: Specify “suspected gastric adenocarcinoma” in the stem to make the malignant intent explicit, although it is already strongly implied.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Prior Roux-en-Y gastric bypass with an inaccessible excluded stomach; refractory iron-deficiency anemia and epigastric pain; capsule endoscopy and CT show a 3.5-cm circumferential, friable lesion/mass in the excluded gastric remnant; no metastatic disease; question explicitly asks for the most appropriate surgical approach considering oncologic control and access limitations.\nThese findings make gastric carcinoma of the excluded remnant highly likely and require oncologic resection with lymphadenectomy and reliable margin control. Open completion gastrectomy including the excluded stomach with Roux-en-Y esophagojejunostomy (D) is the most defensible option, addressing both malignancy and altered anatomy.\nOption A (transgastric endoscopic submucosal dissection) and E (EUS-guided RFA) are inappropriate for suspected invasive cancer in an excluded segment and are non-oncologic. B (laparoscopic wedge resection) is inadequate for a circumferential lesion and proper lymphadenectomy. C (conversion to normal anatomy followed by subtotal gastrectomy) adds unnecessary complexity without oncologic advantage over a direct completion gastrectomy.\nMain medical accuracy issues: none significant; rationale is consistent with standard surgical oncology practice. Minimal fix: Specify “suspected gastric adenocarcinoma” in the stem to make the malignant intent explicit, although it is already strongly implied.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-019", "question": "A 45-year-old man with newly diagnosed mantle cell lymphoma receives R-CHOP followed by high-dose cytarabine. Six months later, he presents with worsening fatigue. CBC shows Hb 7.5 g/dL, MCV 105 fL, WBC 2,000/µL, platelets 40,000/µL. Bone marrow biopsy shows 18% myeloblasts with multilineage dysplasia and complex cytogenetics including monosomy 7. Flow cytometry is consistent with therapy-related myelodysplastic syndrome evolving toward AML. He has an HCT-CI score of 4 and a matched unrelated donor. Which management approach offers the best chance of long-term survival?", "options": ["Continue R-CHOP for mantle cell lymphoma and start azacitidine for t-MDS", "High-intensity induction chemotherapy with 7+3 followed by allogeneic stem cell transplantation in first remission", "Azacitidine plus venetoclax for cytoreduction, then allogeneic stem cell transplantation when feasible", "Supportive care only with transfusions and growth factors due to high transplant risk", "Immediate reduced-intensity allogeneic transplantation without further cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "Therapy-related MDS/AML with complex karyotype has poor prognosis; hypomethylating agent plus venetoclax can achieve remissions with better tolerability than intensive 7+3 in a comorbid patient, allowing subsequent allogeneic transplant for potential cure. Continuing lymphoma chemo (A) ignores aggressive secondary myeloid disease. High-intensity induction (B) risks excess toxicity given HCT-CI 4. Supportive care alone (D) is palliative. Immediate RIC transplant without cytoreduction (E) in 18% blasts is associated with high relapse and graft failure rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 45-year-old with therapy-related MDS evolving toward AML after R-CHOP/high-dose cytarabine; 18% myeloblasts, multilineage dysplasia, complex cytogenetics (monosomy 7); poor-risk secondary disease; HCT-CI score 4 (significant comorbidities) but a matched unrelated donor is available. Goal is long-term survival.\\nThe core issue is choosing a strategy that (1) achieves remission with acceptable toxicity in a comorbid patient and (2) proceeds to allogeneic HSCT, the only curative option for therapy-related MDS/AML with complex karyotype. Option C (azacitidine + venetoclax to achieve lower-toxicity cytoreduction/remission, then allogeneic transplant) aligns with current practice favoring HMA+venetoclax in older/comorbid or t-AML patients, as bridge to transplant.\\nB (7+3 then transplant) is more toxic and less suitable with HCT-CI 4; A inappropriately continues lymphoma therapy and undertreats the myeloid neoplasm; D is palliative and not consistent with “best chance of long-term survival”; E skips cytoreduction with 18% blasts, increasing relapse risk.\\nMain medical accuracy issues: none significant; approach is guideline-consistent and contemporary.\\nMinimal fix: Explicitly note that he is considered unfit for intensive induction (e.g., age/comorbidities) to further justify avoiding 7+3.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 45-year-old with therapy-related MDS evolving toward AML after R-CHOP/high-dose cytarabine; 18% myeloblasts, multilineage dysplasia, complex cytogenetics (monosomy 7); poor-risk secondary disease; HCT-CI score 4 (significant comorbidities) but a matched unrelated donor is available. Goal is long-term survival.\nThe core issue is choosing a strategy that (1) achieves remission with acceptable toxicity in a comorbid patient and (2) proceeds to allogeneic HSCT, the only curative option for therapy-related MDS/AML with complex karyotype. Option C (azacitidine + venetoclax to achieve lower-toxicity cytoreduction/remission, then allogeneic transplant) aligns with current practice favoring HMA+venetoclax in older/comorbid or t-AML patients, as bridge to transplant.\nB (7+3 then transplant) is more toxic and less suitable with HCT-CI 4; A inappropriately continues lymphoma therapy and undertreats the myeloid neoplasm; D is palliative and not consistent with “best chance of long-term survival”; E skips cytoreduction with 18% blasts, increasing relapse risk.\nMain medical accuracy issues: none significant; approach is guideline-consistent and contemporary.\nMinimal fix: Explicitly note that he is considered unfit for intensive induction (e.g., age/comorbidities) to further justify avoiding 7+3.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-020", "question": "A 32-year-old man with long-standing severe atopic dermatitis refractory to topical steroids and cyclosporine is started on dupilumab (anti-IL-4Rα). After 5 months, his skin disease improves markedly, but he develops new-onset peripheral eosinophilia (AEC 3,000/µL), adult-onset asthma, and transient pulmonary infiltrates on CT. ANCA is negative, and biopsy of a skin nodule shows eosinophil-rich vasculitis of small vessels. Which immunologic mechanism best explains this paradoxical adverse event?", "options": ["Unopposed IL-5-mediated eosinophil proliferation due to blockade of IL-4/IL-13 signaling", "Expansion of Th17 cells with increased IL-17 production driven by IL-4 pathway inhibition", "Emergence of autoreactive B cells secondary to impaired regulatory T-cell differentiation", "Type I interferon upregulation resulting from altered JAK-STAT signaling downstream of IL-4Rα", "Loss of IL-31 signaling leading to compensatory mast cell activation and eosinophilia"], "answer": "A", "answer_index": 0, "explanation": "Dupilumab blocks IL-4/IL-13 signaling, which can shift the Th2 cytokine milieu and lead to relative dominance of IL-5-driven eosinophil proliferation and activation, precipitating eosinophilic vasculitis/EGPA-like syndromes in susceptible patients. Th17 expansion (B), autoreactive B cells via Treg failure (C), interferon upregulation (D), or IL-31/mast cell effects (E) do not directly account for marked eosinophilia and small-vessel eosinophilic vasculitis associated with IL-4Rα blockade.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-standing severe atopic dermatitis treated with dupilumab (anti–IL‑4Rα); after clinical response, patient develops marked eosinophilia (AEC 3,000/µL), new adult-onset asthma, transient pulmonary infiltrates, negative ANCA, and eosinophil-rich small-vessel vasculitis on biopsy—an EGPA-like syndrome temporally associated with IL‑4/IL‑13 blockade. Among the mechanisms listed, the only one that directly explains prominent eosinophilia and eosinophilic vasculitis in the context of selective IL‑4/IL‑13 inhibition is relative unopposed IL‑5–mediated eosinophil proliferation and activation (choice A). The other options either do not primarily drive eosinophilia/vasculitis (Th17/IL‑17, type I IFN), are too nonspecific (autoreactive B cells, Treg failure), or are tied to a different cytokine (IL‑31) not central to this adverse effect. No internal contradictions or missing critical data are present; this is a recognized paradoxical effect of dupilumab with a plausible immunologic rationale. Main medical issue: the pathophysiologic mechanism is somewhat theoretical but consistent with current understanding and pharmacovigilance reports. Minimal fix: optionally add a brief phrase in the stem linking IL‑5 to eosinophil maturation to reinforce the mechanistic connection for test-takers.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-standing severe atopic dermatitis treated with dupilumab (anti–IL‑4Rα); after clinical response, patient develops marked eosinophilia (AEC 3,000/µL), new adult-onset asthma, transient pulmonary infiltrates, negative ANCA, and eosinophil-rich small-vessel vasculitis on biopsy—an EGPA-like syndrome temporally associated with IL‑4/IL‑13 blockade. Among the mechanisms listed, the only one that directly explains prominent eosinophilia and eosinophilic vasculitis in the context of selective IL‑4/IL‑13 inhibition is relative unopposed IL‑5–mediated eosinophil proliferation and activation (choice A). The other options either do not primarily drive eosinophilia/vasculitis (Th17/IL‑17, type I IFN), are too nonspecific (autoreactive B cells, Treg failure), or are tied to a different cytokine (IL‑31) not central to this adverse effect. No internal contradictions or missing critical data are present; this is a recognized paradoxical effect of dupilumab with a plausible immunologic rationale. Main medical issue: the pathophysiologic mechanism is somewhat theoretical but consistent with current understanding and pharmacovigilance reports. Minimal fix: optionally add a brief phrase in the stem linking IL‑5 to eosinophil maturation to reinforce the mechanistic connection for test-takers.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]